ACCESSWIRE
06 Aug 2022, 06:25 GMT+10
SAN FRANCISCO, CA / ACCESSWIRE / August 5, 2022 / Hagens Berman urges TG Therapeutics, Inc. (NASDAQ:TGTX) investors who suffered significant losses to submit your losses now. A securities fraud class action has been filed.
Class Period: Jan. 15, 2020 - May 31, 2022
Lead Plaintiff Deadline: Sept. 16, 2022
Visit: www.hbsslaw.com/investor-fraud/TGTX
Contact An Attorney Now: TGTX@hbsslaw.com
844-916-0895
TG Therapeutics, Inc. (NASDAQ: TGTX) Securities Class Action:
The litigation is focused on Defendants' statements about TG's (1) new drug application ('NDA') to the FDA requesting accelerated approval of Umbralisib for treating marginal zone lymphoma ('MZL') and follicular lymphoma ('FL'), (2) biologics license application ('BLA') to the FDA for Ublituximab in combination with Umbralisib (together, 'U2') for treating patients with chronic lymphocytic leukemia ('CLL') (the 'U2 BLA'), (3) supplemental NDA ('sNDA') for Umbralisib to add an indication for CLL and small lymphocytic lymphoma ('SLL') in combination with Ublituximab (the 'U2 sNDA'), and (4) BLA for Ublituximab as a treatment for relapsing forms of multiple sclerosis (the 'Ublituximab RMS BLA').
The complaint alleges Defendants made false and misleading statements and/or failed to disclose material facts, including clinical trial data revealing significant concerns over the safety of Ublituximab and Umbralisib, making it unlikely that the FDA would approve the company's applications in their current forms.
Investors learned the truth through a series of partial disclosures beginning on Nov. 30, 2021, when TG announced that the FDA planned to host a meeting of the Oncologic Drugs Advisory Committee in connection with its review of the U2 BLA and U2sNDA. Then, on April 15, 2022 TG announced it withdrew its U2 BLA/U2sNDA based on safety data. Finally, on June 1, 2022 the FDA announced that it revoked approval for Umbralisib for treating MZL and FL due to safety concerns.
These events drove the price of TG Therapeutics shares sharply lower.
'We're focused on investors' losses and whether TG misrepresented safety data in connection with its submissions to the FDA,' said Reed Kathrein, the Hagens Berman partner leading the investigation.
If you invested in TG Therapeutics and have significant losses, or have knowledge that may assist the firm's investigation, click here to discuss your legal rights with Hagens Berman.
Whistleblowers: Persons with non-public information regarding TG Therapeutics should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email DFS@hbsslaw.com.
# # #
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation law firm focusing on corporate accountability through class-action law. The firm is home to a robust securities litigation practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and fraud. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Contact:
Reed Kathrein, 844-916-0895
SOURCE: Hagens Berman Sobol Shapiro LLP
Get a daily dose of Tennessee Daily news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Tennessee Daily.
More InformationWELLINGTON, New Zealand: During his visit to New Zealand, Ambassador Sujiro Seam, Head of the Delegation of the European Union ...
BANGKOK, Thailand: Instant noodle makers have asked Thailand to allow them to increase their prices to meet rising costs, which ...
NEW YORK, New York - U.S. industrial stocks interrupted their five-day rally on Wednesday with all the major indices losing ...
BANGKOK, Thailand: Thailand seeks to invest $61.97 billion in its industrial eastern region over the next five years, in a ...
JEDDAH, Saudi Arabia: In a Twitter post published this week, Saudi Arabia's Kingdom Holding said it had invested in Russian ...
SYDNEY, NSW, Australia - Stock markets across the Asia Pacific region rallied on Wednesday.In Japan, the Nikkei 225 surged 353.86 ...
As China unleashed live-fire military exercises off the coast of Taiwan, simulating a real "reunification by force" operation in the ...
MIAMI, Florida: Carnival cruise lines, including Carnival Cruise, Princess Cruises and Cunard, have made plans to drop mandatory COVID-19 testing ...
SACRAMENTO, California: California Governor Gavin Newsom is proposing to give a $1.4 billion government loan to extend the life of ...
NEW YORK CITY, New York: The Centers for Disease Control and Prevention relaxed its COVID-19 guidelines last week, driven by ...
NEW YORK CITY, New York: After a study released on Wednesday projected a 15 to 20 percent reduction in the ...
ISLAMABAD, Pakistan - According to information released on Friday, Pakistan Tehrik-e-Insaf, (PTI) has hired a lobbying firm with offices in ...